ABSTRACT. Controversy exists regarding the placental permeability of erythropoietin (Ep), a glycoprotein hormone that regulates red blood cell production in the fetus, newborn, and adult after tissue hypoxia. The purpose of the current study was to determine the placental permeability of biologically active 35S-labeled human recombinant erythropoietin given by bolus injection into the circulation of the fetal lamb. Specific radioactivity in fetal plasma trichloroacetic acid protein precipitate fractions increased 13-fold from preinfusion levels at 6 h (47 2 1.3 to 679 2 237 cpm/mL) and thereafter fell progressively until the study was terminated at 45 h. In contrast, maternal trichloroacetic acid protein precipitate fractions demonstrated no detectable increase in radioactivity at any time. Based on the counting precision, a rise in maternal plasma radioactivity of more than 3 cpm/mL would have been detected (i.e. 0.5% of the 582 cpm/mL rise in the fetal protein precipitate counts at six h). Similar data were obtained with simultaneously administered unlabeled human urinary Ep. We conclude that physiologically significant amounts of Ep do not cross from fetus to mother; hence, maternal Ep level functions as a separate indicator of the adequacy of tissue oxygenation in the maternal compartment. (Pediatr Res 25: 649-651, 1989) Abbreviations Ep, erythropoietin rhEp, recombinant human erythropoietin TCA, trichloroacetic acid Saoz, arterial whole blood oxygen saturation Ep is a glycoprotein hormone (mol wt = 34 000 D) that regulates red blood cell production in the fetus, newborn, and adult (I). In all developmental periods, the primary physiologic stimulus for the release of this hormone is tissue hypoxia, the origin of which can be anemia, hypoxemia, and/or ischemia. The recent availability of recombinant DNA-derived human Ep from engineered mammalian cells has allowed ~g amounts of pure, isotopically labeled Ep to be used for biologic studies (2, 3) .
During human pregnancy, fetal and maternal plasma levels of Ep are increased relative to nonpregnant adults suggesting the presence of relative tissue hypoxia (4-7). Although fetal Ep levels near term before the onset of labor are only slightly increased above those of normal nonpregnant adults (6) , in a variety of pathologic states before and during labor fetal Ep levels may be extraordinarily elevated (8) . The nature of the relationship of Ep levels in the fetus and mother has been the subject of several studies the majority of which indicate that Ep does not cross the placenta (9-13). However, a recent report in which '251-labeled rhEp in the late gestation pregnant mouse was infused in the mothers indicated that intact Ep does cross from mother to fetus (14) . The purpose of the current study was to determine the placental permeability from fetus to mother of radiolabeled 35S-rhEp injected into the fetal lamb.
MATERIALS AND METHODS
Pregnant ewes (n = 5) were all operated on at 123 d of gestation under general anesthesia using intravenous ketamine hydrochloride (400-500 mg/h). At surgery, catheters were inserted into a fetal femoral artery and vein as well as a maternal femoral artery. In the two twin preparations, only one twin was catheterized. Before study, catheter patency was maintained with a concentrated heparin solution (1 000 U/mL). Ampicillin (200 mg/kg) and gentamicin (5 mg/kg) were administered daily to the mothers for the 3 to 4 d after surgery before study. At the end of the study, the ewes and fetuses were killed using ketamine sedation followed by intraarterial thiamylal sodium.
To ascertain the baseline metabolic and oxygenation status, fetal and maternal arterial whole blood samples were drawn for pH, Paoz, Paco2, bicarbonate, hematocrit, Hb, and oxygen saturation (Sao2) before the bolus infusion of 35S-rhEp. To assess stability of the preparations, identical determinations were repeated just before termination of the study. Arterial pH, blood gases, and bicarbonate were measured at 37" C using a Corning 168 blood gas analyzer (Corning Glass Works, Medfield, MA). Hematocrit was measured on whole blood centrifuged for 5 min at 13 400 x g. Hb and Sao2 were measured using a Radiometer OSM-2 hemoximeter (Radiometer America, Inc., Westlake, OH).
Fetal and maternal Ep levels were determined using a double antibody RIA technique in which human and sheep Ep crossreact (4). Because exogenous human Ep was administered, Ep values were read from a human standard curve in a single assay. In the human assay, linear values for Ep concentrations are obtained between 10 and 150 mU/mL. Intraassay coefficients of variation for three samples of pools of human plasma were between 6 and 10%.
rhEp used for bolus injection was intrinsically labeled with 35S-cysteine produced in a line of Chinese hamster ovary cells containing highly amplified copies of the human Ep cDNA and purified as previously described (3). This 35S-rhEp was 95% radiochemically pure as determined by PAGE, had a sp biologic act of 250 000 IU/mg protein as determined by in vitro bioassay (1 5), and had a radio sp act of 150-200 cpm/fmol protein. On the day of study, 35S-rh~p in a dose of 0.8-1.4 x lo6 cpm was injected into the fetal femoral vein over a 1-to 2-min period.
Maternal and fetal arterial blood samples were obtained at selected intervals after the 35S-rhEp bolus: 6, 12, 21, 30, and 45 h. (Only three of the five samples were available for study at the 45-h interval.) The duration of study was selected to allow ample time for the passage of Ep from fetus to mother; the t,,? disappearance rate of Ep in adult sheep has been reported as 9.1 + 3.9 h (mean * SD) (16) . To simulate conditions under which high endogenous fetal plasma Ep levels could contribute to maternal plasma Ep levels, 125 IU of unlabeled Ep (step I human urinary Ep in PBS, Terry Fox Labs, Vancouver, BC, Canada) was injected immediately after the bolus of 35S-rhEp.
Fetal and maternal whole blood samples were centrifuged to remove red cells and 1 .O-mL plasma samples were precipitated in 7-mL screw-top tubes with an equal vol of 20% TCA. After 20 min at 4" C, plasma samples were centrifuged at 4" C at 1 000 rpm for 15 min. Supernatant fractions were decanted into 20-mL scintillation vials with 16 mL of Aquasol-2 added (New England Nuclear, Boston, MA). The remaining TCA protein precipitates were vortexed for 30 s in 3.0 of mL Protosol (New England Nuclear). To dissolve the resulting protein suspension fully, the 7-mL screw-top tubes were capped and placed in a 55" C dry bath overnight. The resulting clear solution was transferred to glass scintillation vials with 16 mL of Aquasol-2 added. The TCA supernatant and precipitate fractions were counted in a liquid scintillation spectrometer (Packard Tri-Carb, model 3385, Hewlett-Packard Co., Palo Alto, CA), using window settings for I4C. All samples were counted for 50-100 min, which produced a mean counting error (2 SD) of 0.5 to 4.1% of the total cpm/mL. In absolute terms, this error was 1.3 to 2.0 cpm/ mL for all maternal and for the fetal prebolus baseline samples.
Statistical analyses were performed using microcomputer software (Statview 11, Abacus Concepts Inc., Berkeley, CA). Within and between group comparisons were done using Student's paired and unpaired t tests. For multiple within-group comparisons with the baseline preinfusion values, repeated measures ANOVA (I-tailed) was used with Dunnett's post hoe testing.
RESULTS
There were no differences between the initial baseline and final fetal or maternal arterial measurements of pH, Pao2, Paco2, bicarbonate, hematocrit, Hb, or SaOz (Table 1 ). All were within normal limits for pregnant ewes and fetal lambs. The fetal and maternal baseline Ep levels were not significantly different (10.0 k 2.7 and 11.1 k 4.8 mU/mL, respectively). At the termination of study, the wt of the fetuses ranged from 3.1 to 3.8 kg.
Plasma sp act of the maternal TCA protein precipitate and supernatant fractions demonstrated no measurable increase in radioactivity at any of the five sampling times after the bolus injection of 35S-rhEp (Table 2 ). This was in marked contrast to the cpm/mL measured in the fetal plasma protein precipitate fractions. These manifest a 13-fold increase from preinfusion levels at 6 h: 47 + 1.3 to 679 + 237 cpm/mL (p < 0.01). All subsequent fetal TCA protein precipitable counts were significantly increased relative to baseline. Similar findings were observed for maternal and fetal levels of unlabeled plasma Ep measured by RIA (Table 3) . Maternal unlabeled Ep levels remained unchanged throughout the study; fetal levels increased significantly 6 h after the bolus infusion of 125 IU human urinary Ep (p < 0.01). In contrast to the fetal 35S TCA precipitate findings, fetal plasma RIA Ep values measured after this time were not significantly different from baseline values.
DISCUSSION
The present study provides direct evidence that the placenta is impermeable to the passage of erythropoietin from fetus to mother. Our data are consistent with the majority of previous work which was performed before the availability of pure, biologically active, labeled Ep (9-13). An exception is the report of Finne (1 7), in which he suggested that endogenously produced Ep could pass from the fetus to the mother in severely affected Rh sensitized pregnancies and from mother to fetus in pregnant mice administered large doses of exogenous Ep. These previous studies have all relied on a variety of less sensitive, less specific bioassays for measuring endogenous and exogenous Ep.
In contrast in the present study, 35S-rhEp was administered to late gestation fetal sheep. Our precision in TCA precipitate counting combined with an estimated pipetting error of =2% allowed us to detect a rise in maternal plasma radioactivity of as little as 3 cpm/mL. This value represents only 0.5% of the 582 cpm/mL rise observed in the fetal TCA protein precipitate at 6 h. Although there was a 20-fold wt difference between the fetus and ewe, the conceptus (fetus and placenta) has a 50% more blood vol/wt than the ewe (1 8). Moreover, because TCA treatment results in the precipitation of low mol wt proteins, including potential Ep breakdown products, TCA precipitate fractions * p < 0.0 1 relative to 0 h (repeated measures ANOVA). Our results differ from those of Koury et a/. (14) , who also administered labeled Ep during pregnancy. These investigators administered biologically active lz5I-rhEp to pregnant mice and observed a rise in fetal levels of less than 10% of the rise in simultaneously measured maternal levels. The authors confirmed with HPLC and PAGE that fetal plasma radioactivity was Ep and not metabolic breakdown products of Ep. If confirmed, these small amounts of Ep transferred to the fetus may be of potential physiologic significance, as some investigators have reported that fetal erythroid precursors are more sensitive than those of the adult to Ep (19) . Several possible reasons exist for the discrepancy between the findings of Koury et al. (14) and those of the present study. In the study of Koury et al., Ep infusate was administered into the maternal circulation; in the present study, it was infused into the fetal circulation. Binding to Ep receptors located on the maternal side of the placenta could be the first step in an endocytotic process similar to that of IgG in many mammalian species (20 Because, with the exception of IgG, molecular size is inversely correlated with placental permeability, it is not unexpected that we did not find Ep crossing from the fetal to the maternal circulation. In an in vitro study in guinea pigs, the syncytiotrophoblast acted as an absolute barrier to proteins larger than 17 000 mol wt infused into the fetal side of the circulation (22) . Gitlin et al. (23) found in the human that of five proteins, albumin, transferrin fibrinogen, and IgM, only IgG crossed from mother to fetus in appreciable amounts. Based on our results and those of others, it appears that in the absence of a specific placental transport receptor for Ep, Ep does not cross the placenta in physiologic amounts.
Morphologic differences in placentas of different species may also account for the discrepancy of our findings with those of Koury et al. (14) . The ovine placenta is four-layered and epitheliochorial as compared with that of the mouse, which is hemotrichorial (24) . Although the choice of the best species for comparison of placental function with the human remains controversial, the sheep may be as appropriate a model as is the guinea pig (25) .
Using a highly sensitive assay system in the near term pregnant sheep, we were unable to demonstrate any passage of 35S-rhEp across the placenta from fetus to mother. Qualitatively similar findings were observed for simultaneously administered unlabeled human urinary Ep. Thus, although the potential for passage of Ep in the opposite direction, i.e. from mother to fetus remains open, physiologically significant amounts of Ep do not cross from fetus to mother. We conclude that the maternal level of Ep is an indicator of the adequacy of tissue oxygenation in the maternal compartment independent of fetal oxygenation. We speculate that elevated plasma Ep levels in human pregnancies reflect true increases in maternal tissue oxygen requirements.
(nett's post hoc testing)
